Sign in

COO on Nasdaq

The Cooper Companies

Logo: The Cooper Companies, Inc., Public domain, via Wikimedia Commons5

American medical device company

The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California. The company consists of two business units, CooperVision (CVI) which manufactures contact lenses, and CooperSurgical (CSI), which manufactures medical devices and fertility and genomic products for the women's healthcare market.3 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

$4.1BRevenue, fiscal 20256
$374.9MNet income, fiscal 20256
1958Founded1

Compare with Bausch & Lomb, National Vision Holdings, Inc. or Alcon, or pick any stock.

  • TickerCOO on Nasdaq1
  • Industrymedical device1
  • HeadquartersSan Ramon1
  • Websitewww.coopercos.com
  • Legal formDelaware corporation1
  • Incorporated inDE7
  • Business address6101 Bollinger Canyon Road, Suite 500, San Ramon, Ca 945837
  • Filer categoryLarge accelerated filer7
  • LEIQJKMVPIGLH7530PCUE204
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressC/O THE PRENTICE-HALL CORPORATION SYSTEM, INC., 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 8881324

See how the biggest companies compare on our leaderboards

The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California. The company consists of two business units, CooperVision (CVI) which manufactures contact lenses, and CooperSurgical (CSI), which manufactures medical devices and fertility and genomic products for the women's healthcare market.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

65.5%Gross margin6
16.7%Operating margin6
9.2%Net margin6
5.1%Revenue growth, 20256
4.6%Return on equity6
0.30×Debt to equity6
$433.7MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

CooperVision brought in 34% of the revenue The Cooper Companies broke down this way in fiscal 2025.

  1. CooperVision$2.7B634%up 5% from 2024
  2. Coopervision$2.7B634%up 5% from 2024
  3. CooperSurgical$1.3B616%up 5% from 2024
  4. Coopersurgical$1.3B616%up 5% from 2024
Business segments by year
Business segments202320242025
CooperVision$2.4B$2.6B$2.7B
Coopervision$2.4B$2.6B$2.7B
CooperSurgical$1.2B$1.3B$1.3B
Coopersurgical$1.2B$1.3B$1.3B

Regions

United States brought in 50% of the revenue The Cooper Companies broke down this way in fiscal 2025.

  1. United States$2.1B650%up 4% from 2024
  2. Europe$1.3B631%up 8% from 2024
  3. Rest Of The World$785.2M619%up 1% from 2024
Regions by year
Regions202320242025
United States$1.8B$2.0B$2.1B
Europe$1.0B$1.2B$1.3B
Rest Of The World$739.8M$773.6M$785.2M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue34¢$1.4B
  • Research and development4¢$172.2M
  • Selling, general and admin40¢$1.6B
  • Other costs8¢$315.6M
  • Income tax5¢$191.6M
  • Profit9¢$374.9M

Out of $4.1B in revenue.6

Where each dollar of operating cash went, fiscal 2025

  • Capital spending46¢$362.4M
  • Share buybacks36¢$290.1M
  • Kept or used elsewhere18¢$143.6M

Out of $796.1M of cash from operations.6

Financial statements

Revenue10111213146$4.1B in 2025+62% since 2018
0$2.0B$4.0B$6.0B2018: $2.5B$2.5B20182019: $2.7B$2.7B2019+5%2020: $2.4B$2.4B2020−8%2021: $2.9B$2.9B2021+20%2022: $3.3B$3.3B2022+13%2023: $3.6B$3.6B2023+9%2024: $3.9B$3.9B2024+8%2025: $4.1B$4.1B2025+5%
Gross profit10111213146$2.7B in 2025+64% since 2018
0$1.0B$2.0B$3.0B2018: $1.6B$1.6B20182019: $1.8B$1.8B2019+8%2020: $1.5B$1.5B2020−13%2021: $2.0B$2.0B2021+27%2022: $2.1B$2.1B2022+9%2023: $2.4B$2.4B2023+10%2024: $2.6B$2.6B2024+10%2025: $2.7B$2.7B2025+3%
Operating income10111213146$682.9M in 2025+69% since 2018
0$200.0M$400.0M$600.0M$800.0M2018: $403.1M$403.1M20182019: $546.7M$546.7M2019+36%2020: $311.8M$311.8M2020−43%2021: $505.8M$505.8M2021+62%2022: $507.6M$507.6M2022+0%2023: $533.1M$533.1M2023+5%2024: $705.7M$705.7M2024+32%2025: $682.9M$682.9M2025−3%
Net income10111213146$374.9M in 2025+168% since 2018
0$1.0B$2.0B$3.0B2018: $139.9M$139.9M20182019: $466.7M$466.7M2019+234%2020: $238.4M$238.4M2020−49%2021: $2.9B$2.9B2021+1135%2022: $385.8M$385.8M2022−87%2023: $294.2M$294.2M2023−24%2024: $392.3M$392.3M2024+33%2025: $374.9M$374.9M2025−4%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2025-10-312024-10-312023-10-31
Net sales$4.1B$3.9B$3.6B
Cost of sales$1.4B$1.3B$1.2B
Gross profit$2.7B$2.6B$2.4B
Selling, general and administrative expense$1.6B$1.5B$1.5B
Research and development expense$172.2M$155.1M$137.4M
Amortization of intangibles$199.2M$201.2M$186.2M
Operating income$682.9M$705.7M$533.1M
Interest expense$100.0M$114.3M$105.3M
Other expense$16.4M$9.1M$14.9M
Income before income taxes$566.5M$582.3M$412.9M
Provision for income taxes (Note 6)$191.6M$190.0M$118.7M
Net income$374.9M$392.3M$294.2M
Basic (in dollars per share)$1.88$1.97$1.49
Diluted (in dollars per share)$1.87$1.96$1.48
Basic (in shares)199.1M shares198.9M shares197.9M shares
Diluted (in shares)200.0M shares200.4M shares199.3M shares

Compare The Cooper Companies with another company

Corporate structure

The Cooper Companies sits at the top of its group. 85 entities, 22 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of The Cooper Companies

  • The Cooper Companies San Ramon, California, United States
    • CooperSurgical (United States) Subsidiary · United States
    • California Cryobank LLC Subsidiary · Delaware, United States
    • California Cryobank Stem Cell Services LLC Subsidiary · Delaware, United States
    • CBR Acquisition Holdings Corp. Subsidiary · Delaware, United States
    • CBR Systems, Inc. Subsidiary · Delaware, United States
    • CCB-DEB LLC Subsidiary · Delaware, United States
    • CCB-Fertility Tech LLC Subsidiary · Delaware, United States
    • CCB-Kitazato LLC Subsidiary · Delaware, United States
    • CCB-MCB LLC Subsidiary · Delaware, United States
    • CCB-NWC LLC Subsidiary · Delaware, United States
    • Cell Care Australia Pty Ltd Subsidiary · Australia
    • Cell Care Australia Pty Ltd, New Zealand Branch Subsidiary · Australia
    • Cooper Global Holdings, Inc. Subsidiary · Delaware, United States
    • Cooper Medical, Inc. Subsidiary · Delaware, United States
    • Cooper Surgical Holdings Ltd. Subsidiary · United Kingdom
    • CooperGenomics, Inc. Subsidiary · Delaware, United States
    • CooperMedical S.r.l Subsidiary · Costa Rica
    • CooperSurgical Distribution B.V. Subsidiary · Netherlands
    • COOPERSURGICAL HOLDINGS LIMITED Subsidiary · Fareham, United Kingdom
    • CooperSurgical, Inc. Subsidiary · Delaware, United States
    • COOPERVISION (UK) HOLDINGS LIMITED Subsidiary · Fareham, United Kingdom
      • COOPERVISION LENS CARE LIMITED Subsidiary · Fareham, United Kingdom
    • CooperVision Australia Pty Limited Subsidiary · Australia
    • CooperVision Canada Corp. Subsidiary · Canada
    • COOPERVISION CL HUNGARY KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG Subsidiary · Pleasanton, California, United States
    • CooperVision CL Kft Subsidiary · Hungary
    • and 55 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What The Cooper Companies reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$3.9B6 Oct 31, 2025$3.6B6 Oct 31, 2024+9.8%
Accumulated depreciation$1.8B6 Oct 31, 2025$1.7B6 Oct 31, 2024+7.7%
Property and equipment, net$2.1B6 Oct 31, 2025$1.9B6 Oct 31, 2024+11.8%
Operating-lease assets (leased space)$270.9M6 Oct 31, 2025$260.7M6 Oct 31, 2024+3.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$110.6M6 Oct 31, 2025$107.6M6 Oct 31, 2024+2.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$3.9B6 Oct 31, 2025$3.8B6 Oct 31, 2024+0.4%
Intangible assets, net (excluding goodwill)$1.6B6 Oct 31, 2025$1.8B6 Oct 31, 2024−11.4%
Indefinite-lived intangibles (excluding goodwill)$1.1M6 Oct 31, 2025$1.8M6 Oct 31, 2024−38.9%
Finite-lived intangibles, gross$3.2B6 Oct 31, 2025$3.2B6 Oct 31, 2024−0.7%
Accumulated amortization$1.6B6 Oct 31, 2025$1.4B6 Oct 31, 2024+13.1%
Finite-lived intangibles, net$1.6B6 Oct 31, 2025$1.8B6 Oct 31, 2024−11.4%

Inventory

ItemLatestA year beforeChange
Inventory, total$846.0M6 Oct 31, 2025$802.7M6 Oct 31, 2024+5.4%
Raw materials$193.1M6 Oct 31, 2025$188.2M6 Oct 31, 2024+2.6%
Work in process$19.9M6 Oct 31, 2025$18.5M6 Oct 31, 2024+7.6%
Finished goods$633.0M6 Oct 31, 2025$596.0M6 Oct 31, 2024+6.2%

Properties, in its own words

The following is a summary of Cooper's principal facilities as of October 31, 2025. We generally lease our office and operations facilities but own several manufacturing and research and development facilities, including 332,172 square feet in the United Kingdom, 347,329 square feet in Costa Rica, 115,000 square feet in Puerto Rico, 512,854 square feet in New York, 80,000 square feet in Arizona and 34,453 square feet in Texas. The following table lists those properties that we lease. Our lease agreements expire at various dates through the year 2045. We believe our properties are suitable and adequate for our businesses.

Location · Approximate LeasedSquare Feet · Operations

The rest of Item 2

AMERICAS

United States:

California · 119,433 · Executive offices; CooperVision manufacturing and administrative offices; CooperSurgical research & development and administrative offices

New York · 137,813 · CooperVision distribution and administrative offices; CooperSurgical administrative offices

New Jersey · 37,700 · CooperSurgical research & development, distribution and administrative offices

Connecticut · 267,737 · CooperSurgical manufacturing, distribution and administrative offices

Arizona · 90,000 · CooperVision manufacturing

Texas · 272,895 · CooperSurgical manufacturing and distribution

Puerto Rico · 682,650 · CooperVision manufacturing, distribution and research & development

Canada · 40,973 · CooperVision manufacturing and administrative office; CooperSurgical distribution, research & development and administrative offices

Other Americas · 89,576 · CooperVision distribution, marketing and administrative offices; CooperSurgical manufacturing, distribution and administrative offices

EMEA

United Kingdom · 352,964 · CooperVision manufacturing, distribution, research & development and administrative offices; CooperSurgical distribution, research & development and administrative offices

Hungary · 421,953 · CooperVision manufacturing and distribution

Belgium · 248,341 · CooperVision distribution; CooperSurgical administrative office

Spain · 181,145 · CooperVision distribution and administrative office; CooperSurgical administrative office

Netherlands · 282,515 · CooperVision administrative offices; CooperSurgical distribution

Other EMEA · 180,686 · CooperVision distribution and administrative office; CooperSurgical administrative office and distribution

ASIA PACIFIC

Japan · 120,669 · CooperVision distribution, marketing, administrative offices and apartment; CooperSurgical marketing and research & development

Australia · 55,557 · CooperVision distribution and marketing; CooperSurgical distribution and research & development

China · 50,663 · CooperVision administrative office, distribution and apartment; CooperSurgical administrative office

Other Asia Pacific · 65,053 · CooperVision distribution, marketing and administrative office; CooperSurgical administrative office

Item 2 of the 10-K filed Dec 5, 2025.18

The story

Parker Montgomery, a lawyer, bought Martin H. Smith Co. in 1958. The company was renamed to Cooper, Tinsley Laboratories, Inc. in 1961. Its name was changed to Cooper Laboratories Inc. in 1967, and entered the contact lens business when it acquired British lens maker GlobalVision in 1972.

In 1980, Cooper Laboratories reorganized into three business groups: CooperVision, CooperCare and CooperBiomedical, with Cooper Medical Devices Corp. added as a fourth group one year later.

The company was renamed The Cooper Companies in 1987. Three years later, it was further restructured into three business units: CooperVision, CooperSurgical and CooperVision Pharmaceuticals (dissolved in 2003).

Currently, the firm operates as two business units: CooperVision and CooperSurgical. CooperVision serves contact lens wearers and eye care practitioners. Products include a range of daily, two-week and monthly disposable contact lenses, and other spherical, toric and multifocal lenses for astigmatism, nearsightedness and farsightedness, and presbyopia.

CooperSurgical is the medical device and fertility and genomics unit of the companies. It became a business unit in 1990 and its focus includes women's health and fertility. It is headquartered in Trumbull, Connecticut.

From Wikipedia’s article on The Cooper Companies, shared under CC BY-SA 4.0.8

Leadership

Who has led The Cooper Companies, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. A. Thomas Bender2006–2007
  2. Nicholas J. Pichotta2006–2014
  3. Robert S. Weiss2008–2018
  4. Paul L. Remmell2012–2017
  5. Albert G. White Iii.2018–2020
  6. Robert D. Auerbach2020–2021

President

  1. A. Thomas Bender2006–2007
  2. Andrew Sedgwick2007–2009
  3. Jeffrey Alan McLean2007–2008
  4. Robert S. Weiss2008–2018
  5. Albert G. White Iii.2018
  6. Robert D. Auerbach2018–2020
  7. Holly R. Sheffield2020–2022
  8. Gerard H. Warner Iii.2022–now

Chief financial officer

  1. John J. Calcagno2006–2007
  2. Steven M. Neil2006–2008
  3. Paul L. Remmell2006–2008
  4. Eugene J. Midlock2008–2011
  5. Gregory W. Matz2011–2016
  6. Albert G. White Iii.2016–2018
  7. Brian G. Andrews2018–now

Chief operating officer

  1. Robert S. Weiss2006–2007
  2. Gregory A. Fryling2006
  3. Paul L. Remmell2008–2012
197019801990200020102020
Board members and other officers (35)

Subsidiaries and ownership

Subsidiaries

Subsidiaries (Exhibit 21)

  • CBR Acquisition Holdings Corp. Delaware9
  • CBR Systems, Inc. Delaware9
  • CCB-DEB LLC Delaware9
  • CCB-Fertility Tech LLC Delaware9
  • CCB-Kitazato LLC Delaware9
  • CCB-MCB LLC Delaware9
  • CCB-NWC LLC Delaware9
  • CVI Contact Lens Pvt. Ltd. India9
  • California Cryobank LLC Delaware9
  • California Cryobank Stem Cell Services LLC Delaware9
  • Cell Care Australia Pty Ltd Australia9
  • Cell Care Australia Pty Ltd, New Zealand Branch Australia9
  • Cooper Global Holdings, Inc. Delaware9
  • Cooper Medical, Inc. Delaware9
  • Cooper Surgical Holdings Ltd. United Kingdom9
  • CooperGenomics, Inc. Delaware9
  • CooperMedical S.r.l Costa Rica9
  • CooperSurgical Distribution B.V. Netherlands9
  • CooperSurgical, Inc. Delaware9
  • CooperVision (UK) Holdings Ltd. United Kingdom9
  • CooperVision Australia Pty Limited Australia9
  • CooperVision CL Kft Hungary9
  • CooperVision Canada Corp. Canada9
  • CooperVision Distribution Srl Belgium9
All 78 listed subsidiaries
  • CooperVision Global Ltd. United Kingdom9
  • CooperVision GmbH Germany9
  • CooperVision Iberia SL Spain9
  • CooperVision International Ltd. United Kingdom9
  • CooperVision Israel Ltd. Israel9
  • CooperVision Italia s.r.l. Italy9
  • CooperVision Japan, Inc. Japan9
  • CooperVision Lens Care Ltd. United Kingdom9
  • CooperVision Ltd. United Kingdom9
  • CooperVision Manufacturing Costa Rica, SRL Costa Rica9
  • CooperVision Manufacturing Limited United Kingdom9
  • CooperVision Manufacturing Puerto Rico LLC Puerto Rico9
  • CooperVision Nederland BV Netherlands9
  • CooperVision Nederland, Belgian Branch Belgium9
  • CooperVision Nordic AB Sweden9
  • CooperVision Optical Trade (Shanghai) Ltd China9
  • CooperVision RUS LLC Russia9
  • CooperVision S.A. (Pty) Limited South Africa9
  • CooperVision S.A.S. France9
  • CooperVision Sarl Switzerland9
  • CooperVision Singapore Pte Ltd Singapore9
  • CooperVision do Brasil Ltda Brazil9
  • Cryobank Holdings LLC Delaware9
  • DEB Donor Egg Bank Canada Ltd Canada9
  • Donor Application LLC Delaware9
  • Eyecare Prime LLC California9
  • Generate CC Australia Pty Ltd Australia9
  • Generate GCP Coinvest LLC Delaware9
  • Generate IP Holdings LLC Delaware9
  • Generate Intermediate LLC Delaware9
  • Generate International LLC Delaware9
  • Generate L Blocker LLC Delaware9
  • Generate LNQ Holdings LLC Delaware9
  • Generate Life Sciences Australia Pty Ltd Australia9
  • Generate Life Sciences LLC Delaware9
  • Generate NQ Blocker LLC Delaware9
  • Generate Parent LLC Delaware9
  • Generate Sperm Bank Canada Ltd. Canada9
  • Insception Biosciences Inc. Canada9
  • Invitro Genetics LLC Delaware9
  • Invitro Genetics Ltd. United Kingdom9
  • LifeGlobal Group LLC Connecticut9
  • Origio A/S Denmark9
  • Paragon Vision Sciences, Inc. Arizona9
  • Reprogenetics LLC Delaware9
  • Research Instruments Ltd. United Kingdom9
  • SC Storage Finance Pty Ltd Australia9
  • SC Storage Holdings Pty Ltd Australia9
  • SC Storage Operations Pty Ltd Australia9
  • Sauflon CL Ltd. United Kingdom9
  • SynergEyes UK Ltd. United Kingdom9
  • SynergEyes, Inc. California9
  • TCC Holdings LLC Delaware9
  • The Cooper Companies, Inc. Delaware9

From Wikidata.1 The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Acquisitions

Ocular Sciences Inc. was acquired by CooperVision in 2005.

CooperSurgical acquired AEGEA Medical, a medical manufacturing company in February 2021. A month later, in March, the company acquired Safe Obstetric Systems, and in December 2021, CooperSurgical acquired Generate Life Sciences for $1.6 billion.

In March 2022, CooperSurgical acquired Cook Medical's reproductive health business for $875 million. During that same year the company acquired EnsEyers, a supplier of orthokeratology and scleral contact lenses.

From Wikipedia’s article on The Cooper Companies, shared under CC BY-SA 4.0.8

Former names

  • COOPER COMPANIES INCAug 1, 1994 to Jun 26, 20197

Timeline

  1. Sep 9, 20268-K Results of operations; Other events73
  2. Jun 4, 20268-K Results of operations; Other events74
  3. May 4, 20268-K Executive or director change75
  4. Apr 8, 20268-K Shareholder vote76
  5. Mar 5, 20268-K Results of operations77
  6. Feb 4, 20268-K Entered a material agreement78
  7. Dec 23, 20258-K Entered a material agreement; Executive or director change; Regulation FD disclosure79
  8. Dec 12, 20258-K Executive or director change80
  9. Dec 4, 20258-K Results of operations; Executive or director change; Regulation FD disclosure81
  10. Aug 27, 20258-K Results of operations82
  11. May 29, 20258-K Results of operations83
  12. Apr 30, 20258-K Executive or director change84
  13. Oct 9, 2020New chief executive Robert D. Auerbach becomes CEO19
  14. May 3, 2018New chief executive Albert G. White Iii. becomes CEO20
  15. Feb 3, 2012New chief executive Paul L. Remmell becomes CEO21
  16. Sep 23, 2008New chief executive Robert S. Weiss becomes CEO22
  17. Oct 26, 2006New chief executive Nicholas J. Pichotta becomes CEO24
  18. Jul 10, 2006New chief executive A. Thomas Bender becomes CEO23
  19. 1958Founded Founded1

Calendar

Coming up

  1. Dec 3, 2026Reports results for the quarter ending Oct/2026 A year earlier it reported $1.15 a share, on Dec 4, 2025.85

When it reported results

  1. Sep 9, 2026Reported quarterly or annual results73
  2. Jun 4, 2026Reported quarterly or annual results74
  3. Mar 5, 2026Reported quarterly or annual results77
  4. Dec 4, 2025Reported quarterly or annual results81
  5. Aug 27, 2025Reported quarterly or annual results82
  6. May 29, 2025Reported quarterly or annual results83
  7. Mar 6, 2025Reported quarterly or annual results86
  8. Dec 5, 2024Reported quarterly or annual results87

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

296 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 44 major events, 166 insider forms, 18 large holders, 48 other. The latest 20:

  1. Sep 17, 20264 PRIMARY DOCUMENT EDGAR
  2. Sep 15, 20264 PRIMARY DOCUMENT EDGAR
  3. Sep 15, 20264 PRIMARY DOCUMENT EDGAR
  4. Sep 15, 20264 PRIMARY DOCUMENT EDGAR
  5. Sep 9, 202610-Q EDGAR
  6. Sep 9, 20268-K EDGAR
  7. Jul 6, 20264 PRIMARY DOCUMENT EDGAR
  8. Jul 6, 20263 PRIMARY DOCUMENT EDGAR
  9. Jun 5, 202610-Q EDGAR
  10. Jun 4, 20268-K EDGAR
  11. May 29, 2026SD EDGAR
  12. May 14, 2026SCHEDULE 13G/A EDGAR
  13. May 4, 20268-K EDGAR
  14. Apr 29, 2026SCHEDULE 13G EDGAR
  15. Apr 21, 20264 PRIMARY DOCUMENT EDGAR
  16. Apr 8, 20268-K EDGAR
  17. Apr 6, 20264 PRIMARY DOCUMENT EDGAR
  18. Apr 6, 20264 PRIMARY DOCUMENT EDGAR
  19. Apr 6, 20264 PRIMARY DOCUMENT EDGAR
  20. Apr 6, 20264 PRIMARY DOCUMENT EDGAR

The 296 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

35 open-market trades by officers, directors and large owners since October 2021: 15 buys and 20 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 16, 2026Kurzius Lawrence ErikDirectorBuy10,000$54.93$549.3KForm 4
Sep 14, 2026Rosebrough Walter M JrDirectorBuy3,000$54.29$162.9KForm 4
Sep 14, 2026Kurzius Lawrence ErikDirectorBuy10,000$53.92$539.2KForm 4
Sep 11, 2026Keel Paul ADirectorBuy4,701$53.18$250.0KForm 4
Sep 11, 2026Rosebrough Walter M JrDirectorBuy7,000$54.11$378.8KForm 4
Dec 22, 2025Lucchese Cynthia LDirectorBuy1,784$84.06$150.0KForm 4
Dec 18, 2025Rivas MariaDirectorBuy1,000$82.13$82.1KForm 4
Dec 17, 2025Kurzius Lawrence ErikDirectorBuy2,000$82.50$165.0KForm 4
Dec 16, 2025Sheffield Holly RPresident, CSIBuy1,230$80.75$99.3KForm 4
Dec 16, 2025White Albert G IIIPresident & CEOBuy10,000$80.80$808.0KForm 4
Sep 29, 2025Kurzius Lawrence ErikDirectorBuy2,000$68.39$136.8KForm 4
Sep 5, 2025White Albert G IIIPresident & CEOBuy10,000$68.39$683.9KForm 4
Sep 5, 2025Warner Gerard H IIIPresident, CooperVision, Inc.Buy1,450$69.23$100.4KForm 4
Sep 2, 2025McBride Daniel GEVP & Chief Operating OfficerBuy3,000$65.04$195.1KForm 4
Sep 2, 2025Andrews Brian GEVP, CFO & TreasurerBuy1,525$65.68$100.2KForm 4
Sep 19, 2024White Albert G IIIPresident & CEOSale114,992$110.53$12.7MForm 4
Sep 10, 2024Ricupati AgostinoSVP & CAOSale1,601$108.03$173.0KForm 4
Sep 5, 2024Andrews Brian GEVP, CFO & TreasurerSale24,788$105.90$2.6MForm 4
Sep 4, 2024McBride Daniel GEVP & Chief Operating OfficerSale114,992$105.48$12.1MForm 4
Mar 18, 2024Ricupati AgostinoSVP & CAOSale54,724$100.89$5.5MForm 4

All 35 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Albert G.White III President & Chief Executive Officer$1.2M$16.1M94
2025Daniel G.McBride Executive Vice President, Chief Operating Officer, General Counsel & Secretary$792.3K$4.8M94
2025Brian G.Andrews Executive Vice President, Chief Financial Officer & Treasurer$734.6K$4.3M94
2025Holly R.Sheffield President, CooperSurgical, Inc.$646.2K$3.7M94
2025Gerard H.Warner III President, CooperVision, Inc.$634.6K$3.6M94
2024Albert G.White III President & Chief Executive Officer$1.1M$15.4M94
2024Daniel G.McBride Executive Vice President, Chief Operating Officer, General Counsel & Secretary$759.6K$4.8M94
2024Brian G.Andrews Executive Vice President, Chief Financial Officer & Treasurer$650.0K$3.7M94
2024Holly R.Sheffield President, CooperSurgical, Inc.$624.7K$3.4M94
2024Gerard H.Warner III President, CooperVision, Inc.$548.7K$3.1M94
2023Albert G.White III President & Chief Executive Officer$1.1M$13.5M94
2023Daniel G.McBride Executive Vice President, Chief Operating Officer, General Counsel & Secretary$745.8K$4.4M94
2023Brian G.Andrews Executive Vice President, Chief Financial Officer & Treasurer$591.7K$3.5M94
2023Holly R.Sheffield President, CooperSurgical, Inc.$570.8K$3.2M94
2023Gerard H.Warner III President, CooperVision, Inc.$491.7K$2.8M94

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.15,029,453$1.1B0.0%−1,588,676
Vanguard Capital Management LLC12,758,769$914.9M0.0%+39,940
State Street Corp8,892,643$637.7M0.0%+124,224
Vanguard Portfolio Management LLC8,669,690$621.7M0.0%−51,641
Browning West LP7,195,428$516.0M30.5%+215,899
Kayne Anderson Rudnick Investment Management LLC5,430,282$389.4M1.2%−1,186,395
Geode Capital Management, LLC5,359,812$382.9M0.0%+48,289
Franklin Resources Inc5,096,888$365.5M0.1%+229,606
Generation Investment Management Llp4,968,673$356.3M3.5%+369,284
Jupiter Topco LLC4,254,267$305.1M0.1%New
Arrowstreet Capital, Limited Partnership4,004,357$287.2M0.1%+1,878,057
Aqr Capital Management LLC4,022,614$285.7M0.1%+295,427
Longview Partners (Guernsey) LTD3,940,007$282.5M4.6%+116,945
UBS Group AG3,932,013$282.0M0.0%+496,795
Citadel Advisors LLC3,872,397$277.7M0.2%+3,679,872
Invesco Ltd.3,685,038$264.3M0.0%+28,227
JANA Partners Management, LP3,582,480$256.9M13.5%+17,322
Wellington Management Group Llp3,468,951$248.8M0.0%+103,044
Dimensional Fund Advisors LP3,341,607$239.6M0.0%+1,272,730
London Co Of Virginia2,898,075$207.8M1.2%+660,930
Diamond Hill Capital Management, LLC (Investment Advisor)2,731,198$195.9M1.6%−667,062
Massachusetts Financial Services Co /ma/2,343,776$187.8M0.1%−274,504
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC2,549,015$182.8M0.0%+18,946
Barclays PLC2,120,075$152.0M0.0%+1,787,487
Bank Of America Corp /de/2,009,835$144.1M0.0%+571,722

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

6 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Jun 5, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−18.6%Report
May 29, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−7.4%Report
Mar 27, 2026Alan ArmstrongRepublican, SenateBuy$1,001 - $15,000−38.7%Report
Dec 10, 2025Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−40.5%Report
May 15, 2025Robert P. Bresnahan, Jr.Republican, HouseSale$1,001 - $15,000+59.6%Report
Jan 5, 2017Thomas R. SuozziDemocratic, HouseSale$15,001 - $50,000+209.5%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How The Cooper Companies is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCOOPER COMPANIES, INC.2
  • CIK0000711404
  • Employer ID (EIN)94-265736818
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company18
  • Incorporated inDelaware18
  • Fiscal year endsOctober 312
  • Industry code (SIC)3851 Ophthalmic Goods2
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
  • Business address6101 Bollinger Canyon Road, Suite 500, San Ramon, CA 945832
  • Phone92546036002
  • Shares outstanding190,155,294 as of Sep 3, 202616
  • Public float$16.2B as of Apr 30, 202518
  • AuditorKPMG LLP, San Francisco, CA PCAOB ID 185; it also attests to the company’s internal control over financial reporting18
  • On EDGAR sinceJan 7, 19942
  • Filings2,297 in all: 4 (1,342), 8-K (347), SC 13G/A (105), 10-Q (99), 4/A (49), SC 13G (46), 3 (36), DEF 14A (33)2
    All 49 form types

    10-K (28), UPLOAD (24), 425 (18), CORRESP (17), 144 (14), DEFA14A (14), S-8 (14), SD (13), SC 13D/A (11), S-3 (8), 3/A (7), 424B3 (7), 10-K/A (5), 10-K405 (5), 10-Q/A (5), 8-K/A (5), 5 (4), PRE 14A (4), 8-A12B (3), ARS (3), S-3/A (3), SCHEDULE 13G/A (3), 424B5 (2), CT ORDER (2), EFFECT (2), S-4 (2), S-4/A (2), SCHEDULE 13G (2), 10-K405/A (1), 25 (1), 424B2 (1), 8-A12B/A (1), CERT (1), DEFR14A (1), POS AM (1), PREM14A (1), PRER14A (1), S-8 POS (1), SC 13E4/A (1), SC TO-I (1), SC TO-I/A (1)

  • Latest filingsAnnual report (10-K) Dec 5, 2025
    Quarterly report (10-Q) Sep 9, 2026
    Proxy statement (DEF 14A) Feb 24, 2026
    Latest 8-K (8-K) Sep 9, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.10 par valueCOONasdaq Global Select Market

From the cover page of the 10-K filed Dec 5, 2025 (Section 12(b) of the Exchange Act).18

Risk factors and legal proceedings

The risks The Cooper Companies names in Item 1A of its 10-K filed Dec 5, 2025: 41 risks under these headings, as written.18

  • Our business faces significant risks. These risks include those described below and may include additional risks and uncertainties not presently known to us or that we currently deem immaterial. Our business, financial condition and results of operations could be materially adversely affected by any of these risks, and the trading prices of our common stock could decline by virtue of these risks. These risks should be read in conjunction with the other information in this report.
  • Risks Relating to Our Business
  • Current market conditions and recessionary pressures in one or more of our markets could impact our ability to grow our business.
  • Inflation could materially adversely affect our business.
  • Our substantial and expanding international operations are subject to uncertainties which could affect our business.
  • Economic and trade sanctions, including tariff and import/export regulations by the U.S. and foreign governments, could make it more difficult or costly for us to conduct our operations or achieve our business objectives.
  • Acquisitions and other strategic transactions that we have made and may make in the future involve numerous risks.
  • We face risks associated with disruption of our manufacturing, distribution and storage operations, including possible failure to develop necessary manufacturing processes, or constrained, idle or excess capacity, which could adversely affect our business.
  • Cybersecurity threats continue to increase in frequency and sophistication; a successful cybersecurity attack could interrupt or disrupt our information technology systems, or those of our third-party service providers, or cause the loss of confidential or protected data which could disrupt our business, force us to incur excessive costs or cause reputational harm.
  • We manage our businesses utilizing multiple complex integrated software and hardware information technology operating systems that are regularly maintained and upgraded; an interruption or disruption to these systems could disrupt our business or force us to incur excessive costs.
  • Pricing pressure from our competitors, customers and changes in third-party coverage and reimbursement may adversely affect demand for our products and negatively impact our operating results.
  • We rely on independent suppliers and third-party logistics providers in our supply chain for raw materials, packaging materials and components, mechanical equipment and some finished goods; we could experience inventory shortages if any of these suppliers encounter a manufacturing or distribution disruption.
The other 30 risks
  • If we fail to protect our intellectual property adequately, our business could suffer.
  • Our products or processes could be subject to claims of infringement of the intellectual property of others.
  • We could experience losses from product liability claims or legal claims relating to our service offerings, including such claims and other losses resulting from sales of counterfeit and other infringing products.
  • If our products or services are not accepted by the market, we will not be able to sustain or expand our business.
  • We operate in the highly competitive health care industry, and we cannot be assured that we will be able to compete successfully.
  • New medical and technological developments may reduce the need for our products.
  • Product innovations are important in the industry in which we operate, and we face the risk of product obsolescence if we are unable to develop new products or gain regulatory approvals or certifications or if our competitors introduce new products.
  • We face risks related to environmental, social and governance matters.
  • Environmental, social and corporate governance issues, including those related to climate change and sustainability, may have an adverse effect on our business and damage our reputation.
  • If we do not retain our key personnel and attract and retain other highly skilled employees, our business could suffer.
  • Provisions of our governing documents and Delaware law may have anti-takeover effects.
  • Risks Relating to Government Regulation of Manufacture and Sale of Our Products and Services.
  • Legislative or regulatory reforms in the United States, Europe or other countries may make it more difficult and costly for us to obtain regulatory clearances, approvals or certifications for our products or to manufacture, market or distribute our products after clearance or approval is obtained.
  • Our products are subject to reporting requirements and recalls, even after receiving regulatory clearance, approval or certification, which could harm our reputation and business.
  • If our manufacturing operations fail to comply with applicable regulations, our manufacturing could be delayed or disrupted, our products could be subject to recall, and sales and profitability could suffer.
  • Our failure to comply with regulatory requirements or to receive regulatory clearance, approval or certification for our products or operations could adversely affect our business.
  • Development and marketing of our products are subject to strict governmental regulation by foreign regulatory agencies, and failure to receive, or delay in receiving, foreign qualifications or certifications could have a material adverse effect on our business.
  • Increased regulatory scrutiny of genetic testing may adversely affect our business through increased costs and risks associated with gaining marketing approvals or certifications and potential impact on demand for our genetic testing services.
  • If we fail to comply with applicable federal, state, local and foreign laboratory licensing requirements, we could lose the ability to perform our genetic tests or experience disruptions to our business.
  • Our HCT/P products are subject to extensive government regulation and our failure to comply with these requirements could cause our business to suffer.
  • Disruptions at the FDA and other government agencies or notified bodies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared or approved or commercialized in a timely manner or at all, which could negatively impact our business.
  • Ethical, legal and social concerns related to the use of genetic information, sperm and egg selection services and stem cells could reduce demand for our service offerings.
  • The costs of complying with the requirements of federal, state and foreign laws pertaining to the privacy and security of personal information, including health related information and the potential liability associated with failure to do so could materially adversely affect our business.
  • Changes in legislation and government regulation of the health care industry both in the United States and internationally, as well as third-party payors' efforts to control the costs of health care could materially adversely affect our business.
  • Laws pertaining to health care fraud and abuse could materially adversely affect our business.
  • Risks Relating to Interest and Foreign Exchange Rates, Debt and Equity
  • Exchange rate fluctuations and foreign currency hedges could adversely affect our financial results.
  • We are vulnerable to interest rate risk with respect to our debt.
  • Our indebtedness could adversely affect our financial health and prevent us from fulfilling our debt obligations.
  • Volatility in the securities markets, interest rates, and other factors could substantially increase our defined benefit plan costs.
  • Risks Relating to Taxes
  • Changes in tax laws, examinations by tax authorities, and changes in our geographic composition of income could adversely affect our financial results.

Legal proceedings

Information regarding legal proceedings is included in Note 11. Contingencies of the Consolidated Financial Statements.

The opening of Item 3, Legal Proceedings.18

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94